• P. N. Patsalos


Pregabalin (Fig. 1) corresponds chemically to S-3-(aminomethyl)-5-methylhexanoic acid with an empirical formula of C8H17NO2 and a molecular weight of 159.2.


  1. 1.
    Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 (Suppl 6):13–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1–168.Google Scholar
  4. 4.
    May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29:789–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Bockbrader HN, Burger PJ, Corrigan BW, Kugler AR, Knapp LE, Garofalo EA, Lalonde RL. Population pharmacokinetic (PK) analysis of commonly prescribed antiepileptic drugs (AEDs) co-administered with pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia. 2001;42 (Suppl 7):84.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations